SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 32.28-3.7%Nov 13 3:54 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bluegreen who wrote (16771)4/8/2004 11:19:06 PM
From: Cacaito  Read Replies (5) of 17367
 
Strange and interesting piece of information: 80% of subjects treated with Raptiva were biologics naive, no other biologics were used before, many without previous systemic therapy at all (from UBS report).

It could mean that patients are mostly responding to their other biologics, and that eventually a group of subjects will start dropping from the other biologics failure, and Raptiva failure will evolve toward the others, eventually a balance of in and outs will happen. And then the combos.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News